TY - JOUR
T1 - A review of circulating tumor DNA in hepatobiliary malignancies
AU - Mody, Kabir
AU - Cleary, Sean P.
N1 - Publisher Copyright:
© 2018 Mody and Cleary.
PY - 2018/6/11
Y1 - 2018/6/11
N2 - Circulating tumor DNA (ctDNA) is released into circulation (blood) specifically from tumor cells undergoing metabolic secretion, apoptosis, or necrosis, carries tumor-specific genetic or epigenetic alterations. Technologies enabling clinical evaluation of ctDNA continue to advance rapidly and allow for the assessment of patient-specific tumoral genetic and epigenetic alterations. This holds great potential for earlier detection of disease, serial monitoring of tumor heterogeneity, identification of therapeutic targets, and evaluation of treatment response and mechanisms of resistance. Hepatobiliary malignancies are often diagnosed late, recur commonly, yield limited available tumor on biopsy, and harbor several genomic alterations with potential therapeutic impacts. Patients suffering from or at risk for these diseases thus stand to benefit immensely from this technology. Herein, we review the limited literature pertaining to the potential for ctDNA technologies in such patients. Patients with these cancers stand to benefit greatly from the application of ctDNA technologies, and concerted efforts at further investigation of such are ongoing and greatly needed.
AB - Circulating tumor DNA (ctDNA) is released into circulation (blood) specifically from tumor cells undergoing metabolic secretion, apoptosis, or necrosis, carries tumor-specific genetic or epigenetic alterations. Technologies enabling clinical evaluation of ctDNA continue to advance rapidly and allow for the assessment of patient-specific tumoral genetic and epigenetic alterations. This holds great potential for earlier detection of disease, serial monitoring of tumor heterogeneity, identification of therapeutic targets, and evaluation of treatment response and mechanisms of resistance. Hepatobiliary malignancies are often diagnosed late, recur commonly, yield limited available tumor on biopsy, and harbor several genomic alterations with potential therapeutic impacts. Patients suffering from or at risk for these diseases thus stand to benefit immensely from this technology. Herein, we review the limited literature pertaining to the potential for ctDNA technologies in such patients. Patients with these cancers stand to benefit greatly from the application of ctDNA technologies, and concerted efforts at further investigation of such are ongoing and greatly needed.
KW - Cholangiocarcinoma
KW - Circulating tumor DNA
KW - Hepatocellular carcinoma
KW - Liver neoplasms/blood
KW - Liver neoplasms/genetics
UR - http://www.scopus.com/inward/record.url?scp=85048629686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048629686&partnerID=8YFLogxK
U2 - 10.3389/fonc.2018.00212
DO - 10.3389/fonc.2018.00212
M3 - Review article
AN - SCOPUS:85048629686
SN - 2234-943X
VL - 8
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - JUN
M1 - 212
ER -